A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection
Public ClinicalTrials.gov record NCT02836470. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate LB1148 for Return of Gastrointestinal Function, Post-Operative Ileus and Intra-Abdominal Adhesions in Subjects Undergoing Elective Bowel Resection
Study identification
- NCT ID
- NCT02836470
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Palisade Bio
- Industry
- Enrollment
- 112 participants
Conditions and interventions
Conditions
Interventions
- LB1148 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2019
- Primary completion
- Sep 5, 2023
- Completion
- Sep 7, 2023
- Last update posted
- Jun 20, 2024
2019 – 2023
United States locations
- U.S. sites
- 28
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 315 | Mobile | Alabama | 36617 | — |
| Site 307 | Yuma | Arizona | 85364 | — |
| Site 329 | Irvine | California | 92868 | — |
| Site 310 | Pasadena | California | 91105 | — |
| Site 302 | Sylmar | California | 91342 | — |
| Site 312 | Torrance | California | 90502 | — |
| Site 306 | Clearwater | Florida | 33756 | — |
| Site 303 | Miami | Florida | 33125 | — |
| Site 331 | Miami | Florida | 33126 | — |
| Site 305 | Miami | Florida | 33142 | — |
| Site 308 | Orlando | Florida | 32804 | — |
| Site 328 | Louisville | Kentucky | 40202 | — |
| Site 321 | Baltimore | Maryland | 21237 | — |
| Site 324 | Burlington | Massachusetts | 01850 | — |
| Site 325 | Rochester | Minnesota | 55905 | — |
| Site 317 | New York | New York | 10029 | — |
| Site 323 | New York | New York | 10075 | — |
| Site 318 | Chapel Hill | North Carolina | 27599 | — |
| Site 301 | Cleveland | Ohio | 44195 | — |
| Site 322 | Pittsburgh | Pennsylvania | 15212 | — |
| Site 330 | Wynnewood | Pennsylvania | 19096 | — |
| Site 327 | Charleston | South Carolina | 29425 | — |
| Site 320 | Dallas | Texas | 75390 | — |
| Site 316 | Fort Worth | Texas | 76104 | — |
| Site 311 | Houston | Texas | 77024 | — |
| Site 319 | Houston | Texas | 77030 | — |
| Sie 309 | Houston | Texas | 77089 | — |
| Site 326 | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02836470, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 20, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02836470 live on ClinicalTrials.gov.